| | | |   | | | | By Ed Silverman Adobe "This could still be a garbage-in garbage-out issue," said Neil Thakur of the ALS Association about the quality of the data in the analysis. Read More | | By Adam Feuerstein Molly Ferguson/STAT The evidence supporting the approval of Amylyx's Albrioza approval isn't ironclad, but it’s stronger than the equivocal data used to approve Aduhelm. Read More | | By Rachel Cohrs J. Scott Applewhite/AP They want the FTC to investigate whether Janssen and Bristol Myers Squibb coordinated price hikes for two blockbuster blood thinners. Read More | | Sponsor content by CATALENT PHARMA SOLUTIONS Catalent launches UpTempo Virtuoso™ The UpTempo Virtuoso™ platform standardizes and streamlines many time-consuming steps in AAV manufacturing to significantly reduce the timeline from gene to clinic and enable rapid first-in-human clinical evaluation. The suspension-based UpTempo Virtuoso platform includes optimized standard protocols for cell culture, transfection, and downstream purification, as well as a standardized bill of materials to simplify the critical supply chain and material qualification. Learn more. | | By Cynthia M. Ho Adobe IP nationalism refers to countries engaging in actions to protect their domestic self-interest with respect to intellectual property. Read More | | By Tara Bannow SAUL LOEB/POOL/AFP via Getty Images Antitrust experts say the FTC’s recent hospital merger challenges don’t show a tougher approach to health care consolidation. Read More | |
No comments